• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The results of a pharmacoeconomic study: incremental cost-effectiveness ratio versus net monetary benefit.

作者信息

Messori Andrea, Trippoli Sabrina

机构信息

HTA Unit, ESTAR, Regional Health Service, Firenze, Italy.

出版信息

Heart. 2017 Nov;103(21):1746. doi: 10.1136/heartjnl-2017-311816.

DOI:10.1136/heartjnl-2017-311816
PMID:29025922
Abstract
摘要

相似文献

1
The results of a pharmacoeconomic study: incremental cost-effectiveness ratio versus net monetary benefit.一项药物经济学研究的结果：增量成本效益比与净货币效益
Heart. 2017 Nov;103(21):1746. doi: 10.1136/heartjnl-2017-311816.
2
Incremental cost-effectiveness ratio and net monetary benefit: Current use in pharmacoeconomics and future perspectives.增量成本效益比与净货币效益：药物经济学中的当前应用及未来展望。
Eur J Intern Med. 2017 Sep;43:e36. doi: 10.1016/j.ejim.2017.05.015. Epub 2017 May 25.
3
Pharmacoeconomics.药物经济学
J Assoc Physicians India. 2002 Aug;50:1057-62.
4
Highly Innovative Drug Program in the Czech Republic: Description and Pharmacoeconomic Results-Cost-Effectiveness and Budget Impact Analyses.捷克共和国的高度创新药物计划：描述与药物经济学结果——成本效益与预算影响分析
Value Health Reg Issues. 2018 Sep;16:92-98. doi: 10.1016/j.vhri.2018.08.003. Epub 2018 Oct 10.
5
Guidelines for performing a pharmacoeconomic analysis.进行药物经济学分析的指南。
Am J Hosp Pharm. 1992 Jul;49(7):1741-7.
6
[Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].[药物经济学分析与奥地利药品定价及报销决策的相关性]
Wien Med Wochenschr. 2006 Dec;156(23-24):612-8. doi: 10.1007/s10354-006-0357-7.
7
Incremental Cost-Effectiveness Ratio and Net Monetary Benefit: Promoting the Application of Value-Based Pricing to Medical Devices-A European Perspective.增量成本效益比与净货币效益：推动基于价值的定价在医疗器械中的应用——欧洲视角
Ther Innov Regul Sci. 2018 Nov;52(6):755-756. doi: 10.1177/2168479018769300. Epub 2018 Apr 15.
8
Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.抗血小板治疗中的药物经济学概念：以氯吡格雷为例理解成本效益分析
J Cardiovasc Pharmacol Ther. 2008 Jun;13(2):107-19. doi: 10.1177/1074248407313151.
9
Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.依普利酮：对其用于心肌梗死后心力衰竭患者的药物经济学评价
Pharmacoeconomics. 2005;23(10):1057-72. doi: 10.2165/00019053-200523100-00008.
10
[Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].新药的成本效益影响报销决策，但仍有改进空间。
Ned Tijdschr Geneeskd. 2010;154:A958.

引用本文的文献

1
Cost-effectiveness of sacituzumab govitecan for hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer based on the EVER-132-002 trial in China.基于中国 EVER-132-002 试验的戈沙妥珠单抗治疗激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌的成本效益
Cost Eff Resour Alloc. 2025 Mar 19;23(1):8. doi: 10.1186/s12962-025-00613-z.
2
Cost-effectiveness analysis of trilaciclib for preventing myelosuppression in small cell lung cancer patients treated with etoposide, carboplatin, and atezolizumab.曲拉西利用于预防接受依托泊苷、卡铂和阿替利珠单抗治疗的小细胞肺癌患者骨髓抑制的成本效益分析。
Am J Cancer Res. 2025 Feb 15;15(2):559-572. doi: 10.62347/SNXD3155. eCollection 2025.
3
Cost-effectiveness analysis of mHealth applications for depression in Germany using a Markov cohort simulation.
使用马尔可夫队列模拟对德国用于抑郁症的移动健康应用程序进行成本效益分析。
NPJ Digit Med. 2024 Nov 17;7(1):321. doi: 10.1038/s41746-024-01324-0.
4
Cost-effectiveness Analysis of Second-Generation Antihistamine 1 Receptor Blockers and Japanese Kampo Shoseiryuto for Treating Perennial Allergic Rhinitis in Outpatient Settings in Japan.第二代抗组胺药1受体阻滞剂与日本汉方制剂柴芍六君子汤治疗日本门诊常年性变应性鼻炎的成本效益分析
Hosp Pharm. 2024 Aug;59(4):436-443. doi: 10.1177/00185787241229152. Epub 2024 Feb 18.
5
Examining chronic kidney disease screening frequency among diabetics: a POMDP approach.探讨糖尿病患者慢性肾脏病筛查频率：一种部分可观测马尔可夫决策过程方法。
Health Care Manag Sci. 2024 Sep;27(3):391-414. doi: 10.1007/s10729-024-09677-4. Epub 2024 Jun 5.
6
Risk-based lung cancer screening in heavy smokers: a benefit-harm and cost-effectiveness modeling study.基于风险的重度吸烟者肺癌筛查：一项获益-危害和成本效益建模研究。
BMC Med. 2024 Feb 19;22(1):73. doi: 10.1186/s12916-024-03292-4.
7
A cost-effectiveness analysis of a South African pregnancy support grant.一项关于南非孕期支持补助金的成本效益分析。
PLOS Glob Public Health. 2024 Feb 8;4(2):e0002781. doi: 10.1371/journal.pgph.0002781. eCollection 2024.
8
Managing Tenders in the Procurement of Advanced Medical Devices: An Original Model Based on the Net Monetary Benefit Combined With Three Clinical Endpoints.先进医疗设备采购中的招标管理：一种基于净货币效益并结合三个临床终点的原创模型。
Cureus. 2023 May 15;15(5):e39062. doi: 10.7759/cureus.39062. eCollection 2023 May.
9
Cost comparison between spinal versus general anesthesia for hip and knee arthroplasty: an incremental cost study.髋关节和膝关节置换术的脊髓麻醉与全身麻醉的成本比较：增量成本研究。
Can J Anaesth. 2022 Nov;69(11):1349-1359. doi: 10.1007/s12630-022-02303-3. Epub 2022 Aug 18.
10
Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease.超越 10 年风险：他汀类药物用于心血管疾病一级预防的成本效益分析。
Circulation. 2022 Apr 26;145(17):1312-1323. doi: 10.1161/CIRCULATIONAHA.121.057631. Epub 2022 Mar 7.